Physician profile
Pushpinder K Gill
NPI 1386180230
$1,895.01
in general payments reported to CMS, 2019-2025
16 companies · $805 in 2025
The $805 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $214 · 2022: $16.67 · 2023: $592 · 2024: $267 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,639 · Long Term Medical Supply Or Device Loan: $25.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,639.05 |
| Long Term Medical Supply Or Device Loan | $25.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $333.79 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $313.38 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Abbvie INC. | $289.83 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $227.19 | 2021-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $225.33 | 2025 | Cobenfy |
| Alkermes, INC. | $192.08 | 2021-2024 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $84.48 | 2023-2025 | Caplyta |
| Lundbeck LLC | $64.57 | 2024-2025 | Rexulti, Abilify Maintena |
| Lilly USA, LLC | $36.63 | 2023 | Mounjaro |
| Baxter Healthcare | $25.05 | 2023 | Hillrom - Cp 150 Resting Electrocardiograph |
| Janssen Pharmaceuticals, INC | $19.73 | 2025 | Invega Sustenna |
| Indivior INC. | $19.03 | 2025 | Sublocade |
| Vanda Pharmaceuticals INC. | $18.54 | 2025 | Hetlioz, Fanapt |
| Eisai INC. | $17.61 | 2021 | |
| Avanir Pharmaceuticals, INC. | $14.92 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushpinder Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.